Microbial strategies for antagonizing Toll-like-receptor signal transduction

Current Opinion in Immunology

Volumn 32, Issue , 2015, Pages 61-70

  Rosadini, Charles V ^a   Kagan, Jonathan C ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MULTIPROTEIN COMPLEX; PROTEIN BINDING; SIGNAL PEPTIDE; TRANSCRIPTION FACTOR;

BACTERIOLOGY; COMPLEX FORMATION; HUMAN; LIGAND BINDING; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; VIROLOGY; ANIMAL; METABOLISM; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS;

ANIMALS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE KINASE KINASES; MICROBIOLOGICAL PHENOMENA; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPROTEIN COMPLEXES; PROTEIN BINDING; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 6; TOLL-LIKE RECEPTORS; TRANSCRIPTION FACTORS;

EID: 84921463388     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.12.011     Document Type: Review

References (102)

1. Bowie A.G., Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol 2008, 8:911-922.
2. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
3. Kagan J.C., Medzhitov R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell 2006, 125:943-955.
4. Bonham K.S., Orzalli M.H., Hayashi K., Wolf A.I., Glanemann C., Weninger W., Iwasaki A., Knipe D.M., Kagan J.C. A promiscuous lipid-binding protein diversifies the subcellular sites of Toll-like receptor signal transduction. Cell 2014, 156:705-716.
5. Kagan J.C. Signaling organelles of the innate immune system. Cell 2012, 151:1168-1178.
6. Kagan J.C., Magupalli V.G., Wu H. SMOCs: supramolecular organizing centres that control innate immunity. Nat Rev Immunol 2014, 14:821-826.
7. Motshwene P.G., Moncrieffe M.C., Grossmann J.G., Kao C., Ayaluru M., Sandercock A.M., Robinson C.V., Latz E., Gay N.J. An oligomeric signaling platform formed by the Toll-like receptor signal transducers MyD88 and IRAK-4. J Biol Chem 2009, 284:25404-25411.
8. Lin S.C., Lo Y.C., Wu H. Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 2010, 465:885-890.
9. Cervantes J.L., Weinerman B., Basole C., Salazar J.C. TLR8: the forgotten relative revindicated. Cell Mol Immunol 2012, 9:434-438.
10. Patterson N.J., Werling D. To con protection: TIR-domain containing proteins (Tcp) and innate immune evasion. Vet Immunol Immunopathol 2013, 155:147-154.
11. Mukherjee A., Morosky S.A., Delorme-Axford E., Dybdahl-Sissoko N., Oberste M.S., Wang T., Coyne C.B. The coxsackievirus B 3C protease cleaves MAVS and TRIF to attenuate host type I interferon and apoptotic signaling. PLoS Pathog 2011, 7:e1001311.
12. Rana R.R., Simpson P., Zhang M., Jennions M., Ukegbu C., Spear A.M., Alguel Y., Matthews S.J., Atkins H.S., Byrne B. Yersinia pestis TIR-domain protein forms dimers that interact with the human adaptor protein MyD88. Microb Pathog 2011, 51:89-95.
13. Askarian F., van Sorge N.M., Sangvik M., Beasley F.C., Henriksen J.R., Sollid J.U., van Strijp J.A., Nizet V., Johannessen M. A Staphylococcus aureus TIR domain protein virulence factor blocks TLR2-mediated NF-kappaB signaling. J Innate Immun 2014, 6:485-498.
14. Bowie A., Kiss-Toth E., Symons J.A., Smith G.L., Dower S.K., O'Neill L.A. A46R and A52R from vaccinia virus are antagonists of host IL-1 and Toll-like receptor signaling. Proc Natl Acad Sci U S A 2000, 97:10162-10167.
15. Stack J., Haga I.R., Schroder M., Bartlett N.W., Maloney G., Reading P.C., Fitzgerald K.A., Smith G.L., Bowie A.G. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J Exp Med 2005, 201:1007-1018.
16. Sengupta D., Koblansky A., Gaines J., Brown T., West A.P., Zhang D., Nishikawa T., Park S.G., Roop R.M., Ghosh S. Subversion of innate immune responses by Brucella through the targeted degradation of the TLR signaling adapter, MAL. J Immunol 2010, 184:956-964.
17. van Lint A.L., Murawski M.R., Goodbody R.E., Severa M., Fitzgerald K.A., Finberg R.W., Knipe D.M., Kurt-Jones E.A. Herpes simplex virus immediate-early ICP0 protein inhibits Toll-like receptor 2-dependent inflammatory responses and NF-kappaB signaling. J Virol 2010, 84:10802-10811.
18. Radhakrishnan G.K., Yu Q., Harms J.S., Splitter G.A. Brucella TIR domain-containing protein mimics properties of the Toll-like receptor adaptor protein TIRAP. J Biol Chem 2009, 284:9892-9898.
19. Snyder G.A., Deredge D., Waldhuber A., Fresquez T., Wilkins D.Z., Smith P.T., Durr S., Cirl C., Jiang J., Jennings W., et al. Crystal structures of the Toll/Interleukin-1 receptor (TIR) domains from the Brucella protein TcpB and host adaptor TIRAP reveal mechanisms of molecular mimicry. J Biol Chem 2014, 289:669-679.
20. Harte M.T., Haga I.R., Maloney G., Gray P., Reading P.C., Bartlett N.W., Smith G.L., Bowie A., O'Neill L.A. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J Exp Med 2003, 197:343-351.
21. Clark K., Nanda S., Cohen P. Molecular control of the NEMO family of ubiquitin-binding proteins. Nat Rev Mol Cell Biol 2013, 14:673-685.
22. Sen J., Liu X., Roller R., Knipe D.M. Herpes simplex virus US3 tegument protein inhibits Toll-like receptor 2 signaling at or before TRAF6 ubiquitination. Virology 2013, 439:65-73.
23. Saito S., Murata T., Kanda T., Isomura H., Narita Y., Sugimoto A., Kawashima D., Tsurumi T. Epstein-Barr virus deubiquitinase downregulates TRAF6-mediated NF-kappaB signaling during productive replication. J Virol 2013, 87:4060-4070.
24. van Gent M., Braem S.G., de Jong A., Delagic N., Peeters J.G., Boer I.G., Moynagh P.N., Kremmer E., Wiertz E.J., Ovaa H., et al. Epstein-Barr virus large tegument protein BPLF1 contributes to innate immune evasion through interference with Toll-like receptor signaling. PLOS Pathog 2014, 10:e1003960.
25. Sanada T., Kim M., Mimuro H., Suzuki M., Ogawa M., Oyama A., Ashida H., Kobayashi T., Koyama T., Nagai S., et al. The Shigella flexneri effector OspI deamidates UBC13 to dampen the inflammatory response. Nature 2012, 483:623-626.
26. Zhang L., Ding X., Cui J., Xu H., Chen J., Gong Y.N., Hu L., Zhou Y., Ge J., Lu Q., et al. Cysteine methylation disrupts ubiquitin-chain sensing in NF-kappaB activation. Nature 2012, 481:204-208.
27. Paquette N., Conlon J., Sweet C., Rus F., Wilson L., Pereira A., Rosadini C.V., Goutagny N., Weber A.N., Lane W.S., et al. Serine/threonine acetylation of TGFbeta-activated kinase (TAK1) by Yersinia pestis YopJ inhibits innate immune signaling. Proc Natl Acad Sci U S A 2012, 109:12710-12715.
28. Reddick L.E., Alto N.M. Bacteria fighting back: how pathogens target and subvert the host innate immune system. Mol Cell 2014, 54:321-328.
29. Halfmann P., Neumann G., Kawaoka Y. The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase. J Infect Dis 2011, 204(Suppl. 3):S953-S956.
30. Wang S., Chen Z., Hu C., Qian F., Cheng Y., Wu M., Shi B., Chen J., Hu Y., Yuan Z. Hepatitis B virus surface antigen selectively inhibits TLR2 ligand-induced IL-12 production in monocytes/macrophages by interfering with JNK activation. J Immunol 2013, 190:5142-5151.
31. Goncalves A., Burckstummer T., Dixit E., Scheicher R., Gorna M.W., Karayel E., Sugar C., Stukalov A., Berg T., Kralovics R., et al. Functional dissection of the TBK1 molecular network. PLoS ONE 2011, 6:e23971.
32. Wang D., Fang L., Li K., Zhong H., Fan J., Ouyang C., Zhang H., Duan E., Luo R., Zhang Z., et al. Foot-and-mouth disease virus 3C protease cleaves NEMO to impair innate immune signaling. J Virol 2012, 86:9311-9322.
33. Wang D., Fang L., Wei D., Zhang H., Luo R., Chen H., Li K., Xiao S. Hepatitis A virus 3C protease cleaves NEMO to impair induction of beta interferon. J Virol 2014, 88:10252-10258.
34. Yamaguchi M., Kitagawa Y., Zhou M., Itoh M., Gotoh B. An anti-interferon activity shared by paramyxovirus C proteins: inhibition of Toll-like receptor 7/9-dependent alpha interferon induction. FEBS Lett 2014, 588:28-34.
35. Le Negrate G. Viral interference with innate immunity by preventing NF-kappaB activity. Cell Microbiol 2012, 14:168-181.
36. Taylor K.E., Mossman K.L. Recent advances in understanding viral evasion of type I interferon. Immunology 2013, 138:190-197.
37. Kim J.C., Lee S.Y., Kim S.Y., Kim J.K., Kim H.J., Lee H.M., Choi M.S., Min J.S., Kim M.J., Choi H.S., et al. HSV-1 ICP27 suppresses NF-kappaB activity by stabilizing IkappaBalpha. FEBS Lett 2008, 582:2371-2376.
38. Graff J.W., Ettayebi K., Hardy M.E. Rotavirus NSP1 inhibits NFkappaB activation by inducing proteasome-dependent degradation of beta-TrCP: a novel mechanism of IFN antagonism. PLoS Pathog 2009, 5:e1000280.
39. Mansur D.S., Maluquer de Motes C., Unterholzner L., Sumner R.P., Ferguson B.J., Ren H., Strnadova P., Bowie A.G., Smith G.L. Poxvirus targeting of E3 ligase beta-TrCP by molecular mimicry: a mechanism to inhibit NF-kappaB activation and promote immune evasion and virulence. PLoS Pathog 2013, 9:e1003183.
40. Vandevenne P., Lebrun M., El Mjiyad N., Ote I., Di Valentin E., Habraken Y., Dortu E., Piette J., Sadzot-Delvaux C. The varicella-zoster virus ORF47 kinase interferes with host innate immune response by inhibiting the activation of IRF3. PLoS ONE 2011, 6:e16870.
41. Wang S., Wang K., Lin R., Zheng C. Herpes simplex virus 1 serine/threonine kinase US3 hyperphosphorylates IRF3 and inhibits beta interferon production. J Virol 2013, 87:12814-12827.
42. Wang K., Ni L., Wang S., Zheng C. Herpes simplex virus 1 protein kinase US3 hyperphosphorylates p65/RelA and dampens NF-kappaB activation. J Virol 2014, 88:7941-7951.
43. Melroe G.T., Silva L., Schaffer P.A., Knipe D.M. Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: potential role in blocking IFN-beta induction. Virology 2007, 360:305-321.
44. Lin R., Genin P., Mamane Y., Sgarbanti M., Battistini A., Harrington W.J., Barber G.N., Hiscott J. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene 2001, 20:800-811.
45. Xing J., Ni L., Wang S., Wang K., Lin R., Zheng C. Herpes simplex virus 1-encoded tegument protein VP16 abrogates the production of beta interferon (IFN) by inhibiting NF-kappaB activation and blocking IFN regulatory factor 3 to recruit its coactivator CBP. J Virol 2013, 87:9788-9801.
46. Gao X., Wan F., Mateo K., Callegari E., Wang D., Deng W., Puente J., Li F., Chaussee M.S., Finlay B.B., et al. Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function. PLoS Pathog 2009, 5:e1000708.
47. Royan S.V., Jones R.M., Koutsouris A., Roxas J.L., Falzari K., Weflen A.W., Kim A., Bellmeyer A., Turner J.R., Neish A.S., et al. Enteropathogenic E. coli non-LEE encoded effectors NleH1 and NleH2 attenuate NF-kappaB activation. Mol Microbiol 2010, 78:1232-1245.
48. Muhlen S., Ruchaud-Sparagano M.H., Kenny B. Proteasome-independent degradation of canonical NFkappaB complex components by the NleC protein of pathogenic Escherichia coli. J Biol Chem 2011, 286:5100-5107.
49. Pearson J.S., Riedmaier P., Marches O., Frankel G., Hartland E.L. A type III effector protease NleC from enteropathogenic Escherichia coli targets NF-kappaB for degradation. Mol Microbiol 2011, 80:219-230.
50. Yen H., Ooka T., Iguchi A., Hayashi T., Sugimoto N., Tobe T. NleC, a type III secretion protease, compromises NF-kappaB activation by targeting p65/RelA. PLoS Pathog 2010, 6:e1001231.
51. Baruch K., Gur-Arie L., Nadler C., Koby S., Yerushalmi G., Ben-Neriah Y., Yogev O., Shaulian E., Guttman C., Zarivach R., et al. Metalloprotease type III effectors that specifically cleave JNK and NF-kappaB. EMBO J 2011, 30:221-231.
52. Newton H.J., Pearson J.S., Badea L., Kelly M., Lucas M., Holloway G., Wagstaff K.M., Dunstone M.A., Sloan J., Whisstock J.C., et al. The type III effectors NleE and NleB from enteropathogenic E. coli and OspZ from Shigella block nuclear translocation of NF-kappaB p65. PLoS Pathog 2010, 6:e1000898.
53. Kim D.W., Lenzen G., Page A.L., Legrain P., Sansonetti P.J., Parsot C. The Shigella flexneri effector OspG interferes with innate immune responses by targeting ubiquitin-conjugating enzymes. Proc Natl Acad Sci U S A 2005, 102:14046-14051.
54. Pruneda J.N., Smith F.D., Daurie A., Swaney D.L., Villen J., Scott J.D., Stadnyk A.W., Le Trong I., Stenkamp R.E., Klevit R.E., et al. E2~Ub conjugates regulate the kinase activity of Shigella effector OspG during pathogenesis. EMBO J 2014, 33:437-449.
55. DiPerna G., Stack J., Bowie A.G., Boyd A., Kotwal G., Zhang Z., Arvikar S., Latz E., Fitzgerald K.A., Marshall W.L. Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors. J Biol Chem 2004, 279:36570-36578.
56. Newman R.M., Salunkhe P., Godzik A., Reed J.C. Identification and characterization of a novel bacterial virulence factor that shares homology with mammalian Toll/interleukin-1 receptor family proteins. Infect Immun 2006, 74:594-601.
57. Li H., Xu H., Zhou Y., Zhang J., Long C., Li S., Chen S., Zhou J.M., Shao F. The phosphothreonine lyase activity of a bacterial type III effector family. Science 2007, 315:1000-1003.
58. Mazurkiewicz P., Thomas J., Thompson J.A., Liu M., Arbibe L., Sansonetti P., Holden D.W. SpvC is a Salmonella effector with phosphothreonine lyase activity on host mitogen-activated protein kinases. Mol Microbiol 2008, 67:1371-1383.
59. Mukherjee S., Keitany G., Li Y., Wang Y., Ball H.L., Goldsmith E.J., Orth K. Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 2006, 312:1211-1214.
60. Tobe T., Beatson S.A., Taniguchi H., Abe H., Bailey C.M., Fivian A., Younis R., Matthews S., Marches O., Frankel G., et al. An extensive repertoire of type III secretion effectors in Escherichia coli O157 and the role of lambdoid phages in their dissemination. Proc Natl Acad Sci U S A 2006, 103:14941-14946.
61. Matsumoto H., Young G.M. Translocated effectors of Yersinia. Curr Opin Microbiol 2009, 12:94-100.
62. Datta A., Sinha-Datta U., Dhillon N.K., Buch S., Nicot C. The HTLV-I p30 interferes with TLR4 signaling and modulates the release of pro- and anti-inflammatory cytokines from human macrophages. J Biol Chem 2006, 281:23414-23424.
63. Peri P., Mattila R.K., Kantola H., Broberg E., Karttunen H.S., Waris M., Vuorinen T., Hukkanen V. Herpes simplex virus type 1 Us3 gene deletion influences toll-like receptor responses in cultured monocytic cells. Virol J 2008, 5:140.
64. Yokoyama R., Itoh S., Kamoshida G., Takii T., Fujii S., Tsuji T., Onozaki K. Staphylococcal superantigen-like protein 3 binds to the Toll-like receptor 2 extracellular domain and inhibits cytokine production induced by Staphylococcus aureus, cell wall component, or lipopeptides in murine macrophages. Infect Immun 2012, 80:2816-2825.
65. Bardoel B.W., Vos R., Bouman T., Aerts P.C., Bestebroer J., Huizinga E.G., Brondijk T.H., van Strijp J.A., de Haas C.J. Evasion of Toll-like receptor 2 activation by staphylococcal superantigen-like protein 3. J Mol Med (Berl) 2012, 90:1109-1120.
66. Bestebroer J., van Kessel K.P., Azouagh H., Walenkamp A.M., Boer I.G., Romijn R.A., van Strijp J.A., de Haas C.J. Staphylococcal SSL5 inhibits leukocyte activation by chemokines and anaphylatoxins. Blood 2009, 113:328-337.
67. Kilian M., Reinholdt J., Lomholt H., Poulsen K., Frandsen E.V. Biological significance of IgA1 proteases in bacterial colonization and pathogenesis: critical evaluation of experimental evidence. APMIS 1996, 104:321-338.
68. Clementi C.F., Murphy T.F. Non-typeable Haemophilus influenzae invasion and persistence in the human respiratory tract. Front Cell Infect Microbiol 2011, 1:1.
69. Wilensky A., Tzach-Nahman R., Potempa J., Shapira L., Nussbaum G. Porphyromonas gingivalis gingipains selectively reduce CD14 expression, leading to macrophage hyporesponsiveness to bacterial infection. J Innate Immun 2014.
70. de Oliveira V.L., Almeida S.C., Soares H.R., Crespo A., Marshall-Clarke S., Parkhouse R.M. A novel TLR3 inhibitor encoded by African swine fever virus (ASFV). Arch Virol 2011, 156:597-609.
71. Xiang Z., Li L., Lei X., Zhou H., Zhou Z., He B., Wang J. Enterovirus 68 3C protease cleaves TRIF to attenuate antiviral responses mediated by Toll-like receptor 3. J Virol 2014, 88:6650-6659.
72. Li K., Foy E., Ferreon J.C., Nakamura M., Ferreon A.C., Ikeda M., Ray S.C., Gale M., Lemon S.M. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005, 102:2992-2997.
73. Abe T., Kaname Y., Hamamoto I., Tsuda Y., Wen X., Taguwa S., Moriishi K., Takeuchi O., Kawai T., Kanto T., et al. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 2007, 81:8953-8966.
74. Ahmad H., Gubbels R., Ehlers E., Meyer F., Waterbury T., Lin R., Zhang L. Kaposi sarcoma-associated herpesvirus degrades cellular Toll-interleukin-1 receptor domain-containing adaptor-inducing beta-interferon (TRIF). J Biol Chem 2011, 286:7865-7872.
75. Salcedo S.P., Marchesini M.I., Degos C., Terwagne M., Von Bargen K., Lepidi H., Herrmann C.K., Santos Lacerda T.L., Imbert P.R., Pierre P., et al. BtpB, a novel Brucella TIR-containing effector protein with immune modulatory functions. Front Cell Infect Microbiol 2013, 3:28.
76. Cirl C., Wieser A., Yadav M., Duerr S., Schubert S., Fischer H., Stappert D., Wantia N., Rodriguez N., Wagner H., et al. Subversion of Toll-like receptor signaling by a unique family of bacterial Toll/interleukin-1 receptor domain-containing proteins. Nat Med 2008, 14:399-406.
77. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D., et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280:734-737.
78. Jones R.M., Wu H., Wentworth C., Luo L., Collier-Hyams L., Neish A.S. Salmonella AvrA coordinates suppression of host immune and apoptotic defenses via JNK pathway blockade. Cell Host Microbe 2008, 3:233-244.
79. Arbibe L., Kim D.W., Batsche E., Pedron T., Mateescu B., Muchardt C., Parsot C., Sansonetti P.J. An injected bacterial effector targets chromatin access for transcription factor NF-kappaB to alter transcription of host genes involved in immune responses. Nat Immunol 2007, 8:47-56.
80. Trosky J.E., Li Y., Mukherjee S., Keitany G., Ball H., Orth K. VopA inhibits ATP binding by acetylating the catalytic loop of MAPK kinases. J Biol Chem 2007, 282:34299-34305.
81. Otsuka M., Kato N., Moriyama M., Taniguchi H., Wang Y., Dharel N., Kawabe T., Omata M. Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. Hepatology 2005, 41:1004-1012.
82. Ma Y., Jin H., Valyi-Nagy T., Cao Y., Yan Z., He B. Inhibition of TANK binding kinase 1 by herpes simplex virus 1 facilitates productive infection. J Virol 2012, 86:2188-2196.
83. Wang G., Chen G., Zheng D., Cheng G., Tang H. PLP2 of mouse hepatitis virus A59 (MHV-A59) targets TBK1 to negatively regulate cellular type I interferon signaling pathway. PLoS ONE 2011, 6:e17192.
84. Chen R.A., Ryzhakov G., Cooray S., Randow F., Smith G.L. Inhibition of IkappaB kinase by vaccinia virus virulence factor B14. PLoS Pathog 2008, 4:e22.
85. Unterholzner L., Sumner R.P., Baran M., Ren H., Mansur D.S., Bourke N.M., Randow F., Smith G.L., Bowie A.G. Vaccinia virus protein C6 is a virulence factor that binds TBK-1 adaptor proteins and inhibits activation of IRF3 and IRF7. PLoS Pathog 2011, 7:e1002247.
86. Schroder M., Baran M., Bowie A.G. Viral targeting of DEAD box protein 3 reveals its role in TBK1/IKKepsilon-mediated IRF activation. EMBO J 2008, 27:2147-2157.
87. Ashida H., Kim M., Schmidt-Supprian M., Ma A., Ogawa M., Sasakawa C. A bacterial E3 ubiquitin ligase IpaH9.8 targets NEMO/IKKgamma to dampen the host NF-kappaB-mediated inflammatory response. Nat Cell Biol 2010, 12:66-73. sup 99 61-69.
88. Mittal R., Peak-Chew S.Y., McMahon H.T. Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc Natl Acad Sci U S A 2006, 103:18574-18579.
89. Bauhofer O., Summerfield A., Sakoda Y., Tratschin J.D., Hofmann M.A., Ruggli N. Classical swine fever virus Npro interacts with interferon regulatory factor 3 and induces its proteasomal degradation. J Virol 2007, 81:3087-3096.
90. Okumura A., Alce T., Lubyova B., Ezelle H., Strebel K., Pitha P.M. HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 2008, 373:85-97.
91. Doehle B.P., Chang K., Rustagi A., McNevin J., McElrath M.J., Gale M. Vpu mediates depletion of interferon regulatory factor 3 during HIV infection by a lysosome-dependent mechanism. J Virol 2012, 86:8367-8374.
92. Hotter D., Kirchhoff F., Sauter D. HIV-1 Vpu does not degrade interferon regulatory factor 3. J Virol 2013, 87:7160-7165.
93. Yu Y., Hayward G.S. The ubiquitin E3 ligase RAUL negatively regulates type i interferon through ubiquitination of the transcription factors IRF7 and IRF3. Immunity 2010, 33:863-877.
94. Lefort S., Soucy-Faulkner A., Grandvaux N., Flamand L. Binding of Kaposi's sarcoma-associated herpesvirus K-bZIP to interferon-responsive factor 3 elements modulates antiviral gene expression. J Virol 2007, 81:10950-10960.
95. Joo C.H., Shin Y.C., Gack M., Wu L., Levy D., Jung J.U. Inhibition of interferon regulatory factor 7 (IRF7)-mediated interferon signal transduction by the Kaposi's sarcoma-associated herpesvirus viral IRF homolog vIRF3. J Virol 2007, 81:8282-8292.
96. Sparrer K.M., Pfaller C.K., Conzelmann K.K. Measles virus C protein interferes with Beta interferon transcription in the nucleus. J Virol 2012, 86:796-805.
97. Irie T., Kiyotani K., Igarashi T., Yoshida A., Sakaguchi T. Inhibition of interferon regulatory factor 3 activation by paramyxovirus V protein. J Virol 2012, 86:7136-7145.
98. Lu L.L., Puri M., Horvath C.M., Sen G.C. Select paramyxoviral V proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappaB kinase epsilon (IKKe)/TBK1. J Biol Chem 2008, 283:14269-14276.
99. Barro M., Patton J.T. Rotavirus NSP1 inhibits expression of type I interferon by antagonizing the function of interferon regulatory factors IRF3, IRF5, and IRF7. J Virol 2007, 81:4473-4481.
100. Arnold M.M., Patton J.T. Diversity of interferon antagonist activities mediated by NSP1 proteins of different rotavirus strains. J Virol 2011, 85:1970-1979.
101. Zhu H., Zheng C., Xing J., Wang S., Li S., Lin R., Mossman K.L. Varicella-zoster virus immediate-early protein ORF61 abrogates the IRF3-mediated innate immune response through degradation of activated IRF3. J Virol 2011, 85:11079-11089.
102. Sloan E., Henriquez R., Kinchington P.R., Slobedman B., Abendroth A. Varicella-zoster virus inhibition of the NF-kappaB pathway during infection of human dendritic cells: role for open reading frame 61 as a modulator of NF-kappaB activity. J Virol 2012, 86:1193-1202.